Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes
نویسندگان
چکیده
منابع مشابه
Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes
Type 2 diabetes mellitus (DM2) is characterized by excessive hepatic gluconeogenesis, increased insulin resistance and a progressive inability of pancreatic beta cells to produce sufficient insulin. DM2 evolves as a progression from normal glucose tolerance, to impaired glucose tolerance (IGT) to frank diabetes mellitus, reflecting the establishment of insulin resistance and beta cell dysfuncti...
متن کاملAlogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus
Alogliptin is a selective dipeptidyl peptidase-4 inhibitor recently marketed for once-daily administration in the treatment of type 2 diabetes mellitus (T2DM). Fixed-dose combinations of alogliptin with both metformin and pioglitazone are also commercially available, providing a measure of convenience in addition to an effective mode of delivering combination therapy to improve glycemic control...
متن کاملCombination of Linagliptin and Metformin for the Treatment of Patients with Type 2 Diabetes
Type 2 diabetes mellitus (T2DM) is a progressive condition requiring long-term treatment. Most patients with T2DM are unable to maintain normoglycemia using metformin alone; thus, combination therapy is a pivotal part of disease management. Addition of the dipeptidyl peptidase-4 inhibitor linagliptin, with its proven efficacy, low propensity for hypoglycemia, and weight neutrality, has been sho...
متن کاملPharmacogenomic approach in type 2 diabetes treatment
Introduction: Type 2 diabetes (T2D) is chronic health caused by the interaction between genetic and environmental factors that results in high blood glucose. The evidence-based guidelines for diabetes management are mainly based on lifestyle changes, control of risk factors, and the management of blood glucose levels. Although numerous antidiabetic agents have been developed over time, T2D trea...
متن کاملClinical utility in the treatment of type 2 diabetes with the saxagliptin/metformin fixed combination
Fixed-dose combination (FDC) products represent a widely accepted approach to type 2 diabetes treatment, given that monotherapies sometimes fail to meet the treatment targets - obtaining a sustained reduction in micro- and macrovascular complications. Saxagliptin (SAXA)/metformin (MET) FDC tablets can be used either alone or in combination with glyburide, thiazolidinediones, or insulin. It has ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Vascular Health and Risk Management
سال: 2007
ISSN: 1178-2048
DOI: 10.2147/vhrm.s936